DarioHealth Corp. (DRIO)
USD 0.65
(-9.08%)
USD 0.65
(-9.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 62.17 Million USD | -6.65% |
| 2022 | 66.46 Million USD | -17.39% |
| 2021 | 80.45 Million USD | 148.2% |
| 2020 | 32.41 Million USD | 59.67% |
| 2019 | 20.3 Million USD | 4.36% |
| 2018 | 19.45 Million USD | 23.67% |
| 2017 | 15.73 Million USD | 53.15% |
| 2016 | 10.27 Million USD | 50.09% |
| 2015 | 6.84 Million USD | -20.85% |
| 2014 | 8.64 Million USD | -36.25% |
| 2013 | 13.56 Million USD | 241.24% |
| 2012 | 3.97 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 18.82 Million USD | -4.4% |
| 2024 Q1 | 19.69 Million USD | 38.5% |
| 2023 FY | 62.04 Million USD | -6.65% |
| 2023 Q3 | 16.15 Million USD | 0.39% |
| 2023 Q2 | 16.09 Million USD | 3.33% |
| 2023 Q4 | 14.21 Million USD | -11.99% |
| 2023 Q1 | 15.57 Million USD | 32.65% |
| 2022 Q4 | 11.74 Million USD | -28.28% |
| 2022 Q3 | 16.37 Million USD | -11.46% |
| 2022 Q2 | 18.49 Million USD | -6.87% |
| 2022 Q1 | 19.85 Million USD | -10.61% |
| 2022 FY | 66.46 Million USD | -17.39% |
| 2021 FY | 80.45 Million USD | 148.2% |
| 2021 Q1 | 15.4 Million USD | 60.28% |
| 2021 Q2 | 19.51 Million USD | 26.63% |
| 2021 Q3 | 23.32 Million USD | 19.55% |
| 2021 Q4 | 22.21 Million USD | -4.77% |
| 2020 FY | 32.41 Million USD | 59.67% |
| 2020 Q1 | 10.89 Million USD | 116.95% |
| 2020 Q2 | 4.75 Million USD | -56.31% |
| 2020 Q4 | 9.61 Million USD | 34.43% |
| 2020 Q3 | 7.15 Million USD | 50.26% |
| 2019 Q2 | 5.68 Million USD | -3.94% |
| 2019 Q4 | 5.02 Million USD | 36.74% |
| 2019 FY | 20.3 Million USD | 4.36% |
| 2019 Q1 | 5.92 Million USD | 10.1% |
| 2019 Q3 | 3.67 Million USD | -35.44% |
| 2018 Q4 | 5.37 Million USD | 22.26% |
| 2018 Q2 | 6.24 Million USD | 82.35% |
| 2018 Q1 | 3.42 Million USD | -7.03% |
| 2018 FY | 19.45 Million USD | 23.67% |
| 2018 Q3 | 4.39 Million USD | -29.6% |
| 2017 FY | 15.73 Million USD | 53.15% |
| 2017 Q4 | 3.68 Million USD | 13.07% |
| 2017 Q3 | 3.26 Million USD | -27.2% |
| 2017 Q2 | 4.47 Million USD | 3.87% |
| 2017 Q1 | 4.31 Million USD | 35.27% |
| 2016 FY | 10.27 Million USD | 50.09% |
| 2016 Q1 | 1.82 Million USD | 13.6% |
| 2016 Q2 | 2.46 Million USD | 35.42% |
| 2016 Q3 | 2.79 Million USD | 13.42% |
| 2016 Q4 | 3.18 Million USD | 13.94% |
| 2015 Q4 | 1.6 Million USD | -33.65% |
| 2015 Q2 | 1.27 Million USD | -17.45% |
| 2015 Q1 | 1.54 Million USD | 4.6% |
| 2015 FY | 6.84 Million USD | -20.85% |
| 2015 Q3 | 2.41 Million USD | 89.19% |
| 2014 Q3 | 1.92 Million USD | -35.89% |
| 2014 Q4 | 1.47 Million USD | -23.05% |
| 2014 Q2 | 2.99 Million USD | 12.37% |
| 2014 Q1 | 2.66 Million USD | -26.94% |
| 2014 FY | 8.64 Million USD | -36.25% |
| 2013 Q1 | 3.07 Million USD | 93.46% |
| 2013 Q2 | 3.59 Million USD | 16.9% |
| 2013 Q4 | 3.65 Million USD | 12.75% |
| 2013 Q3 | 3.23 Million USD | -9.94% |
| 2013 FY | 13.56 Million USD | 241.24% |
| 2012 Q2 | 866.34 Thousand USD | 75.11% |
| 2012 Q4 | 1.59 Million USD | 55.4% |
| 2012 FY | 3.97 Million USD | 0.0% |
| 2012 Q1 | 494.74 Thousand USD | 0.0% |
| 2012 Q3 | 1.02 Million USD | 18.11% |
| 2001 Q2 | 19.51 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 58.271% |
| Prenetics Global Limited | 60.73 Million USD | -2.365% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -282.086% |
| CareDx, Inc | 277.76 Million USD | 77.617% |
| Exact Sciences Corporation | 2.06 Billion USD | 96.983% |
| Exagen Inc. | 52.29 Million USD | -18.894% |
| Inotiv, Inc. | 246.9 Million USD | 74.819% |
| Guardant Health, Inc. | 901.62 Million USD | 93.104% |
| Biodesix, Inc. | 77.41 Million USD | 19.693% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -1484.798% |
| Precipio, Inc. | 13.63 Million USD | -355.881% |
| iSpecimen Inc. | 16.27 Million USD | -281.962% |
| Natera, Inc. | 938.98 Million USD | 93.379% |
| Aspira Women's Health Inc. | 24.11 Million USD | -157.829% |
| Standard BioTools Inc. | 113.48 Million USD | 45.217% |
| 23andMe Holding Co. | 420.73 Million USD | 85.223% |
| Castle Biosciences, Inc. | 242.78 Million USD | 74.392% |
| Personalis, Inc. | 128.14 Million USD | 51.482% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 43.748% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -277.11% |
| OpGen, Inc. | 30.65 Million USD | -102.796% |
| T2 Biosystems, Inc. | 41.49 Million USD | -49.836% |
| Myriad Genetics, Inc. | 600.1 Million USD | 89.64% |
| ICON Public Limited Company | 755.64 Million USD | 91.772% |
| NeoGenomics, Inc. | 341.25 Million USD | 81.781% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -282.086% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 94.311% |
| RadNet, Inc. | 268.87 Million USD | 76.877% |
| MDxHealth SA | 71.25 Million USD | 12.747% |
| Psychemedics Corporation | 11.33 Million USD | -448.553% |
| Illumina, Inc. | 3.81 Billion USD | 98.369% |
| Check-Cap Ltd. | 19.28 Million USD | -222.357% |
| Twist Bioscience Corporation | 354.18 Million USD | 82.446% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 63.833% |
| Sera Prognostics, Inc. | 39.91 Million USD | -55.756% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -490.957% |
| OPKO Health, Inc. | 574.68 Million USD | 89.181% |
| Medpace Holdings, Inc. | 187.68 Million USD | 66.873% |
| Neogen Corporation | 405.23 Million USD | 84.658% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -430.994% |
| Prenetics Global Limited | 60.73 Million USD | -2.365% |
| Mainz Biomed B.V. | 27.15 Million USD | -128.962% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -609.345% |
| Trinity Biotech plc | 46.49 Million USD | -33.72% |
| Neuronetics, Inc. | 82.25 Million USD | 24.418% |
| Sotera Health Company | 300.46 Million USD | 79.308% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -609.345% |